Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-11-10 Interim / Quarterly Rep…
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT' (Interim Report) for the period January-September 2022. It contains comprehensive financial statements, including income statements, balance sheet items, and detailed management commentary on clinical trials and business operations. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-10 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT' and covers the period 'January - September 2022'. It contains detailed financial statements (Net sales, Operating loss, Loss after tax, Loss per share, Equity/assets ratio, Cash and cash equivalents), management commentary, and operational updates. It meets the criteria for an Interim/Quarterly Report as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2022
2022-11-10 English
Cantargias CAN10 visar positiva effekter i modeller av systemisk skleros i de nya data som presenteras vid ACR Convergence 2022
Regulatory Filings Classification · 95% confidence The document is a press release ("Pressmeddelande") dated November 8, 2022, announcing new preclinical results for the drug candidate CAN10 in systemic sclerosis, which will be presented at the ACR Convergence 2022 conference. It details scientific findings, quotes the CEO and a collaborating professor, and mentions future plans (Phase I study in early 2023). Crucially, it concludes with a statement indicating it is information the company is required to make public under EU market abuse regulation, and it is not a formal regulatory filing like a 10-K, a full quarterly report (IR), or a proxy statement. Since it is an announcement of scientific/research progress and not a formal financial report, dividend notice, or management change, it best fits the category for general regulatory announcements or miscellaneous filings that don't fit elsewhere, which is Regulatory Filings (RNS). It is too detailed and long to be a simple Report Publication Announcement (RPA) which usually just points to another document.
2022-11-08 Swedish
Cantargia’s CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2022
Regulatory Filings Classification · 99% confidence The document is a press release dated November 8, 2022, announcing new preclinical data for the drug candidate CAN10 regarding its positive activity in systemic sclerosis models, which was presented at the ACR Convergence 2022 conference. It details scientific findings, quotes the CEO and a collaborating professor, and mentions future plans (initiating clinical studies in 2023). This content is characteristic of an announcement regarding research progress or scientific findings, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a formal investor presentation (IP). Since it is a press release detailing scientific/research updates, it fits best under the general 'Regulatory Filings' (RNS) category as a general corporate/research update, or potentially an Investor Presentation (IP) if it were the actual slides, but since it's a press release *about* the presentation, RNS is the most appropriate general category for non-standard announcements not covered by other specific codes (like ER, DIV, CAP, etc.). Given the options, RNS serves as the best fit for a scientific press release update.
2022-11-08 English
Cantargia presents new data at SITC 2022 supporting nadunolimab’s promising antitumor clinical efficacy
Regulatory Filings Classification · 99% confidence The document is a press release dated November 7, 2022, announcing that Cantargia will present new data on its drug nadunolimab at the SITC 2022 meeting (November 8-12, 2022). It details the scientific findings (mechanism of action, reduction of tumor-promoting molecules) and references ongoing clinical trials (CANFOUR). This is a standard corporate communication updating investors on research progress and upcoming presentations, not a formal regulatory filing like a 10-K, a comprehensive Interim Report (IR), or a formal Earnings Release (ER). Since it is an announcement about data being presented at a scientific meeting, it fits best under the general category of Investor Presentation (IP) or, given its format as a press release detailing research updates, it could also be considered a general Regulatory Filing (RNS) if IP is too specific for research updates. However, the content is highly focused on presenting scientific data and clinical progress, which aligns closely with the purpose of an Investor Presentation (IP) or a general update. Given the context of presenting data at a major conference, 'Investor Presentation' (IP) is a strong fit, although it is presented as a press release. Since it is not a formal presentation document itself but an announcement *about* a presentation, and it contains significant business/research updates, it is often classified as a general Regulatory Filing (RNS) or sometimes an Investor Presentation (IP). Because it is a press release detailing scientific progress and upcoming presentation details, and not the presentation slides themselves, RNS is the safest general classification for non-standard updates, but IP captures the intent better. Given the detailed scientific nature, I will lean towards IP as it is information intended for investors regarding product development, even if it's a press release format announcing a poster presentation.
2022-11-07 English
Cantargia presenterar nya data på SITC 2022 som stödjer nadunolimabs lovande kliniska antitumöreffekter
Regulatory Filings Classification · 99% confidence The document is a press release from Cantargia AB dated November 7, 2022, announcing that new data regarding their drug nadunolimab will be presented at the SITC 2022 conference (November 8-12, 2022). It details preclinical and clinical findings (from the CANFOUR study) supporting the drug's efficacy, mentions upcoming studies (Precision PromiseSM, planned NSCLC study for 2023), and states that the abstract/poster details will be made available on their website after the presentation. This document is an announcement about scientific data presentation and ongoing clinical trial updates, rather than the full financial report (10-K), a quarterly report (IR), or a formal earnings release (ER). Since it is an announcement regarding scientific/clinical progress and data presentation, it fits best under the general category of Investor Relations or Regulatory Filings. Given the context of presenting scientific data and updates on clinical trials, it is most closely aligned with general investor communication, but since it is not a formal financial report or a specific management/board change, and it is a formal announcement, 'Regulatory Filings' (RNS) is the most appropriate fallback for non-standard, yet material, company news, or it could be considered Investor Relations material. However, since it is a formal press release announcing data presentation and clinical progress, and there isn't a specific 'Clinical Update' code, RNS serves as the best fit for material, non-financial regulatory/investor news that isn't a specific report type listed.
2022-11-07 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.